Skip to main content
Signal8

GH Research PLC (GHRS)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

GH Research PLC logo

GH Research PLC

NASDAQ:GHRSHealthcare
AH-2.16%$19.50
Close$19.93-1.73%
Mkt Cap$1.37B
Float44.11M
O/S68.64M
VOL298K sh
$ Vol$5.79M
RVOL0.90×
Inst Own75.3%
EarningsNov 5 · Tomorrow
Dilution
GH Research PLC logoNASDAQ:GHRSAH$19.50-2.16%
Historical Data
DateOpenHighLowCloseVolume
Nov 4, 202620.7320.8618.2919.93298,369
Nov 3, 202620.6421.3820.0520.28476,163
Nov 2, 202620.9121.2719.9520.50542,842
Oct 30, 202621.2621.4020.3920.86305,401
Oct 29, 202620.7722.1320.7421.50345,219
Oct 28, 202619.9120.7919.5220.71198,764
Oct 27, 202619.1820.2218.7520.02299,980
Oct 26, 202618.1619.3118.0719.18306,079
Oct 23, 202618.4618.5917.5418.07699,432
Oct 22, 202618.8319.0018.4318.50329,179
Oct 21, 202619.2219.8118.8018.91393,900
Oct 20, 202618.3019.4318.1119.16277,233
Oct 19, 202618.2219.0718.0218.28323,288
Oct 16, 202618.9219.3218.0518.15162,612
Oct 15, 202618.7519.3918.4818.81276,721
Oct 14, 202618.6419.1918.2918.56304,385
Oct 13, 202619.8819.9018.7218.85425,519
Oct 12, 202621.0521.2320.0120.02229,892
Oct 9, 202620.6621.3020.4521.11146,044
Oct 8, 202620.9421.0719.8720.45334,266
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$40.00+100.7%
Low $39High $65
Ratings Distribution
BUY
9
HOLD
0
SELL
0
TOTAL9
Insider Trades
InsiderTypeShares
Schonharting Florian profile photoSchonharting FlorianGrant/Award2.3K
Moore Duncan profile photoMoore DuncanGrant/Award2.2K
Hanley Dermot John profile photoHanley Dermot JohnGrant/Award2.2K
Forer Michael profile photoForer MichaelGrant/Award2.2K
Forer Michael profile photoForer MichaelGrant/Award100.0K
Shareholders
75.3%
Institutional
(66)
21.9%
Insiderⓘ
(5)
11.2%
5%+ Owners
(3)
of which 1.9% rests on schedules older than 24 months (1 holder)
-
Unattributed (incl. retail)ⓘ
Institutional75.3%
Insider21.9%
5%+ Beneficial11.2%
Sources: 13F, Form 4, 13D/13GO/S: 68.6M · checked 4 Nov 2026 · market-data provider
Insiders & Institutional Holders

Insiders

Top institutional holders

About

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions.

The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD).

Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients.

Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Key Metrics
Market Cap$1.37B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership75.33%

based on 68.64M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryIEIE
IPO DateJun 25, 2021
Shares Outstanding68.64M
Float44.11M
52-Week Range
$12.04$31.44
$19.93(41st percentile)
Volume
Average Daily Volume339.80K
298.37K today vs 339.80K avg(-12%)

30d Avg

339.80K

60d Avg

315.12K

90d Avg

298.49K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...